CompletedNot Applicable

D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

United States54 participantsStarted 2009-08

Plain-language summary

This study seeks to examine the effects of D-cycloserine augmentation on cognitive remediation for patients diagnosed with schizophrenia. We will test the hypotheses that D-cycloserine will significantly improve cognitive performance, negative symptoms, and measures of functioning compared to placebo when combined with eight weeks of cognitive remediation. We expect that these effects will persist when assessed at six-month follow up.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female * Age 18-65 years * Diagnosis of schizophrenia or schizoaffective disorder, depressed type * Stable dose of antipsychotic for at least 4 weeks * Able to provide informed consent * Able to complete a cognitive battery * Able to perform the cognitive remediation exercises Exclusion Criteria: * Current treatment with clozapine * Dementia * Seizure disorder * Unstable medical illness * Renal insufficiency measured as eGFR \>60mg/dL/min * Active substance abuse: positive urine toxic screen * Pregnancy, nursing, or unwilling to use appropriate birth control measures during participation if female and fertile.

What they're measuring

Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS)

Timeframe: Baseline vs. Week 8

Scale for Assessment of Negative Symptoms (SANS)

Timeframe: Baseline vs. Week 8

Auditory Discrimination Task: Interstimulus Interval (ISI)

Timeframe: Baseline vs. Week 8

Trial details

NCT IDNCT00963924

SponsorMassachusetts General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-05

Results submitted2014-06-23

View on ClinicalTrials.gov More Schizophrenia trials